{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:06:58Z","timestamp":1778778418981,"version":"3.51.4"},"reference-count":34,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,5,30]]},"DOI":"10.1536\/ihj.18-392","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T22:03:18Z","timestamp":1558044198000},"page":"728-735","source":"Crossref","is-referenced-by-count":28,"title":["Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet"],"prefix":"10.1536","volume":"60","author":[{"given":"Tomonari","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiji","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"},{"name":"Department of Basic Medicine, Nagano College of Nursing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.","DOI":"10.1172\/JCI116972"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Zinman B, Wanner C, Lachin JM, <i>et al<\/i>. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med 2015; 373: 2117-28.","DOI":"10.1056\/NEJMoa1504720"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Neal B, Perkovic V, Mahaffey KW, <i>et al<\/i>. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med 2017; 377: 644-57.","DOI":"10.1056\/NEJMoa1611925"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Suzuki M, Takeda M, Kito A, <i>et al<\/i>. Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014; 4: e125.","DOI":"10.1038\/nutd.2014.20"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagae A, Fujita M, Kawarazaki H, Matsui H, Ando K, Fujita T. Effect of high fat loading in Dahl salt-sensitive rats. Clin Exp Hypertens 2009; 31: 451-61.","DOI":"10.1080\/10641960902825487"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sharma N, Okere IC, Barrows BR, <i>et al<\/i>. High-sugar diets increase cardiac dysfunction and mortality in hypertension compared to low-carbohydrate or high-starch diets. J Hypertens 2008; 26: 1402-10.","DOI":"10.1097\/HJH.0b013e3283007dda"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mattson DL, Meister CJ, Marcelle ML. Dietary protein source determines the degree of hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2005; 45: 736-41.","DOI":"10.1161\/01.HYP.0000153318.74544.cc"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gallego B, Ar\u00e9valo MA, Flores O, L\u00f3pez-Novoa JM, P\u00e9rez-Barriocanal F. Renal fibrosis in diabetic and aortic-constricted hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1823-9.","DOI":"10.1152\/ajpregu.2001.280.6.R1823"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takemoto M, Egashira K, Tomita H, <i>et al<\/i>. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-7.","DOI":"10.1161\/01.HYP.30.6.1621"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Miyoshi T, Nakamura K, Yoshida M, <i>et al<\/i>. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol 2014; 13: 43.","DOI":"10.1186\/1475-2840-13-43"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakamura K, Miura D, Saito Y, <i>et al<\/i>. Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice. PLoS One 2017; 12: e0181009.","DOI":"10.1371\/journal.pone.0181009"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus. Int Heart J 2017; 58: 475-80.","DOI":"10.1536\/ihj.17-191"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 2016; 15: 157.","DOI":"10.1186\/s12933-016-0473-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 2017; 104: 298-310.","DOI":"10.1016\/j.freeradbiomed.2017.01.035"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose Cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017; 136: 1643-58.","DOI":"10.1161\/CIRCULATIONAHA.117.030012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nakagaito M, Joho S, Ushijima R, Nakamura M, Hirai T, Kinugawa K. Successful withdrawal from dobutamine by canagliflozin in a diabetic patient with Stage D heart failure. Int Heart J 2017; 58: 978-81.","DOI":"10.1536\/ihj.16-644"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tikkanen I, Narko K, Zeller C, <i>et al<\/i>. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.","DOI":"10.2337\/dc14-1096"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Muskiet MHA, van Bommel EJ, van Raalte DH. Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. Lancet Diabetes Endocrinol 2016; 4: 188-9.","DOI":"10.1016\/S2213-8587(15)00457-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Suzuki M, Honda K, Fukazawa M, <i>et al<\/i>. Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012; 341: 692-701.","DOI":"10.1124\/jpet.112.191593"},{"key":"20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","volume":"157","year":"2016","unstructured":"20. Obata A, Kubota N, Kubota T, <i>et al<\/i>. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology 2016; 157: 1029-42.","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nagata T, Fukazawa M, Honda K, <i>et al<\/i>. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab 2013; 304: E414-23.","DOI":"10.1152\/ajpendo.00545.2012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Prior LJ, Davern PJ, Burke SL, Lim K, Armitage JA, Head GA. Exposure to a high-fat diet during development alters leptin and ghrelin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension 2014; 63: 338-45.","DOI":"10.1161\/HYPERTENSIONAHA.113.02498"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yokono M, Takasu T, Hayashizaki Y, <i>et al<\/i>. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014; 727: 66-74.","DOI":"10.1016\/j.ejphar.2014.01.040"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother 2014; 15: 1501-15.","DOI":"10.1517\/14656566.2014.935764"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nishimura R, Tanaka Y, Koiwai K, <i>et al<\/i>. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 2015; 14: 11.","DOI":"10.1186\/s12933-014-0169-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shimada A, Hanafusa T, Yasui A, <i>et al<\/i>. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab 2018; 20: 2190-9.","DOI":"10.1111\/dom.13351"},{"key":"27","unstructured":"27. Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab 2018; 20: 2515-22."},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Shimazu T, Hirschey MD, Newman J, <i>et al<\/i>. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013; 339: 211-4.","DOI":"10.1126\/science.1227166"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Aubert G, Martin OJ, Horton JL, <i>et al<\/i>. The failing heart relies on ketone bodies as a fuel. Circulation 2016; 133: 698-705.","DOI":"10.1161\/CIRCULATIONAHA.115.017355"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bedi KC Jr, Snyder NW, Brandimarto J, <i>et al<\/i>. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 2016; 133: 706-16.","DOI":"10.1161\/CIRCULATIONAHA.115.017545"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Uchihashi M, Hoshino A, Okawa Y, <i>et al<\/i>. Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure. Circ Heart Fail 2017; 10.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004417"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Nakamura K, Fushimi K, Kouchi H, <i>et al<\/i>. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98: 794-9.","DOI":"10.1161\/01.CIR.98.8.794"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A 1995; 92: 4862-6.","DOI":"10.1073\/pnas.92.11.4862"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Shi X, Li X, Li D, <i>et al<\/i>. \u03b2-hydroxybutyrate activates the NF-\u03baB signaling pathway to promote the expression of pro-inflammatory factors in calf hepatocytes. Cell Physiol Biochem 2014; 33: 920-32.","DOI":"10.1159\/000358664"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/3\/60_18-392\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:06:07Z","timestamp":1559361967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/3\/60_18-392\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.18-392","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]}}}